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ARTICLE
End-of-Life Decisions in Dutch Neonatal
Intensive Care Units
A. A. Eduard Verhagen, MD, JD, PhD; Jozef H. H. M. Dorscheidt, JD, PhD; Bernadette Engels, RN;
Joep H. Hubben, JD, PhD; Pieter J. Sauer, MD, PhD
Objective: To clarify the practice of end-of-life deci-
sion making in severely ill newborns.
Design: Retrospective descriptive study with face-to-
face interviews.
Setting:The 10 neonatal intensive care units in theNeth-
erlands from October 2005 to September 2006.
Patients: All 367 newborn infants who died in the first
2 months of life in Dutch neonatal intensive care units.
Adequate documentation was available in 359 deaths.
Outcome Measures: Presence of end-of-life deci-
sions, classification of deaths in 3 groups, and physi-
cians’ considerations leading to end-of-life decisions.
Results: An end-of-life decision preceded death in 95%
of cases, and in 5% treatment was continued until death.
Of all of the deaths, 58% were classified as having no
chance of survival and 42%were stabilized newbornswith
poor prognoses.Withdrawal of life-sustaining therapywas
the main mode of death in both groups. One case of de-
liberate ending of life was found. In 92% of newborns
with poor prognoses, end-of-life decisions were based on
patients’ future quality of life and mainly concerned fu-
ture suffering. Considerations regarding the infant’s pres-
ent state were made in 44% of infants.
Conclusions: Virtually all deaths in Dutch neonatal in-
tensive care units are preceded by the decision to with-
draw life-sustaining treatment and many decisions are
based on future quality of life. The decision to deliber-
ately end the life of a newborn may occur less fre-
quently than was previously assumed.
Arch Pediatr Adolesc Med. 2009;163(10):895-901
T HE INCREASING ABILITY TOsave and extend the lives ofnewborns with technol-ogy have created discus-sions about the role of phy-
sicians in making decisions regarding the
timing and modes of death and dying of
newborns. End-of-life decisions are those
made by physicians that result or prob-
ably result in causing or hastening death.
They include the decision to withhold or
withdraw life-sustaining treatment and the
decision to deliberately end a newborn’s
life with lethal drugs. The deaths of many
newborns are often preceded by an end-
of-life decision.1-6 Most studies describ-
ing end-of-life practices do not make the
important distinction between withhold-
ing or withdrawing treatment in situa-
tions in which death is imminent or the
newborn is moribund and the situation in
which this takes place in stabilized new-
borns for quality-of-life reasons.Only a few
studies have reported details about what
the physicians’ considerations leading to
end-of-life decisions are and how they are
used. Moreover, only a very small number
of publications from the Netherlands and
Flanders have reported some details about
the considerations that lead to the deci-
sion to deliberately end a newborn’s life.4,7,8
As a consequence, real insight in medical
end-of-life practice has remained limited.
Also, comparing outcomes between units
is difficult. For example, a higher survival
rate, and possibly a higher disability rate,
may be seen if most extremely premature
babies are aggressively resuscitated and
withdrawal of care is less frequently of-
fered in a particular unit.9 With the pur-
pose of clarifying end-of-life practice in
severely ill newborns in the Netherlands,
we performed a nationwide retrospective
study to determine when and how physi-
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METHODS
We performed a retrospective descriptive study of Dutch end-
of-life practices in severely ill newborns. Clinical care for these
newborns is centralized in 10 level III neonatal intensive care
units (NICUs). In the Netherlands, physicians are considered
to be ultimately responsible for end-of-life decisions.
NEWBORN AND STUDY CHARACTERISTICS
We reviewed the files of 367 newborns who died in the first 2
months of life in 10 NICUs in the Netherlands from October
2005 to September 2006 according to the Dutch perinatal reg-
istry. Infants who died immediately after birth in the delivery
roomwere not included. The patients were eligible for the study
when a medical file was available for review. We found 359
deaths with complete documentation and extracted informa-
tion from themedical files on birth weight, gestational age, day
of death, and diagnoses (using both clinical data and autopsy
materials when available). We examined the attending physi-
cians’ daily notes and death summaries to determine whether
or not death had occurred with a preceding end-of-life deci-
sion.We defined end-of-life decisions asmedical decisionswith
the effect or the probable effect of hastening death. They in-
cluded decisions to withhold or withdraw life-sustaining treat-
ment and to deliberately end the life of a newborn. Deliberate
ending of a life was defined as administering lethal drugs to
end or shorten the life of a newborn. With respect to deliber-
ate ending of life, we focused on newborn infants who were
physiologically stable to facilitate comparison with our earlier
reports.8,10
CLASSIFICATION OF DEATHS
We used the physicians’ motives for withholding or withdraw-
ing life-sustaining treatment as documented in the files to cat-
egorize the newborns as group I, II, or III in accordance with a
2-dimensional classification from the literature.11,12 One re-
searcher (B.E.) reviewed all files to ensure consistency of clas-
sification. The classification is based on the infant’s prognosis
anddependencyon intensive care for physiologic stability.Group
I encompasses physiologically unstable infants whose death is
imminent. Newborns who are actually dying (heart rate falling,
blood pressure dropping, and oxygen saturation dropping) are
included as are those with inoperable life-threatening congeni-
tal defects or with diseases that the medical team considers un-
treatable. Group II consists of physiologically stabilized inten-
sive care–dependent newborns with very poor prognoses.
Newborns in this group have a theoretical chance of survival,
but the predicted quality of life is very poor. Many newborn in-
fants with severe hypoxic ischemic encephalopathy are in-
cluded in this group together with newborns with chromo-
somal or neurological disease and extremepremature infantswith
grade IV intracranial bleedings with clinical symptoms. Group
III encompasses stable newborns with very poor prognoses and
severe suffering who were not dependent on intensive care.
First, we identified the patients belonging to group I. Next,
we held interviews with the attending physicians of all new-
borns who did not clearly fall into group I to categorize them
as belonging to group I, II, or III. Finally, we used a semi-
structured interview containing both closed- and open-ended
questions to cross-check the assigned category and to ascer-
tain the physicians’ considerations that led to each prognoses-
based end-of-life decision. We asked the physicians to de-
scribe the end-of-life decision-making process and to pay special
attention to the considerations used for the decision. The con-
siderations were grouped into categories derived from the lit-
erature post hoc13,14 and cross-checked again for accuracy with
the physician. We requested the physicians to consult the in-
fants’ medical files during the interviews. An experienced pe-
diatrician (A.A.E.V.) interviewed the physicians, with 1 inter-
view covering multiple infants. The interviews lasted between
30 and 45minutes per patient and they were recorded and ana-
lyzed separately by 2 researchers (A.A.E.V. and B.E.). A subset
of interviews took place in the presence of a qualified legal
scholar ( J.H.H.M.D.). In these, the physicians were asked
whether or not their motives for an end-of life decision were
related to legal considerations and if so, to which.Wewill sepa-
rately report on the outcomes of this part of the interviews as
well as about which treatments were withdrawn and the use
of medication as a part of end-of-life decisions.
We assured the physicians that the interviewwould be held
anonymously. The interval between the end-of-life decision and
the interview was 3 to 14 months. The study design complied
with Dutch legislation on medical file research.
STATISTICAL ANALYSIS
Wecompared thecausesofdeathbyusing the2 test for categori-
cal variables. P .05 was considered statistically significant.
RESULTS
Of the 367newbornswhodied during the 12-month study
period in theDutchNICUs, complete documentationwas
available for 359 deaths (98%). The main demographic
data and patient characteristics are presented in Table1.
The main causes of death in full-term patients were as-
phyxia (47%) and congenital malformations (37%)
(Table 2). The most common cause of death in infants
younger than 30weeks of gestational agewasmulti-organ
failure after sepsis/necrotizing enterocolitis (34%), fol-
lowedby complications of extremeprematurity (31%).The
distribution of causes of death was similar in all 10 units.
Table 1. Characteristics of 359 Newborns Who Died
Before 2 Months in 10 Dutch NICUs During 12 Months














Age at death, d
Early neonatal death, 7 215 (60)
Late neonatal death, 7-27 107 (30)
Postneonatal death, 27 37 (10)
Abbreviation: NICU, neonatal intensive care unit.
aBirth weight–specific neonatal mortality rate for the Netherlands during
the study period: less than 500 g, 91%; 500 to 1000 g, 38%; 1000 to 1500 g,
4.9%; 1500 to 2500 g, 0.96%; and 2500 g or greater, 0.04%.15 Data on birth
weight were missing in 2 cases.
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Of 359 deaths, 340 (95%) were preceded by an end-
of-life decision and 19 (5%) of the infants died while re-
ceiving cardiopulmonary resuscitation. Eighty-eight per-
cent of end-of-life decisions included withdrawal of
treatment, often combined with some form of withhold-
ing of treatment, while 12% included only the decision
to withhold treatment.
A total number of 208 of 359 deaths (58%) were clas-
sified as having no chance of survival (group I) and 150
(42%) as having poor prognoses (group II) (Figure).
There was no difference in the percentage between pa-
tients in groups I and II between the 10 centers. One new-
born with type II osteogenesis imperfecta was classified
as not being intensive care dependent but as having a poor
prognosis and severe suffering (group III). The attend-
ing physician intentionally increased themorphine dose
until death occurred after it became evident that the pa-
tient’s intolerable suffering could not be relieved other-
wise. They issued a certificate declaring the newborn’s
natural death. Themedical team at the unit reviewed the
case several weeks after the infant’s death and con-
cluded that in retrospect, their practice could best be de-
scribed as deliberate ending of life. The case was not re-
ported to the legal authorities. Comparison of causes of
death between infants in groups I and II showed that con-
genital malformation caused death more often in group
I and asphyxia caused death significantly more often in
group II (P .001) (Table 3).
In 56 of 359 patients (16%), 2 end-of-life decisions
were made. The physician’s first decision not to inten-
sify treatment because adding treatment was dispropor-
tionalwas followed by the final decision towithdraw treat-
ment because clinical deterioration had occurred. The
median interval between both decisions was 24 hours
(range, 0.4-425 hours). Ten of these patients were ini-
tially categorized in group II but were changed to group
I at the time of the final end-of-life decision.
Interviews were held with 80 physicians who cared
for 147 of the 150 newborns. Data were missing on 3
deaths because we were unable to find the 2 physicians
involved. The number of patients cared for by 1 physi-
cian ranged from 1 to 4 (mean, 1.8).
Table4presents the quality-of-life considerations used
by the physicians in end-of-life decisionmaking. Inmost
cases (119 of 147) more than 1 consideration was used.
367 Deaths identified in 10 hospitals with NICUs



















Figure. Study flowchart. NICU indicates neonatal intensive care unit.
Table 2. Cause of Death by Gestational Age in Newborns Younger Than 2 Months
Cause of Deatha
No. of Primary Organ Dysfunctions
Total, No. (%)Brain Heart/Circulation Lungs MOF
30 wk (n=123)b
Asphyxia 1 0 0 9 10 (8)
Congenital anomalies 0 1 4 3 8 (7)
Sepsis/necrotizing enterocolitis 1 2 2 37 42 (34)
Extreme prematurityc 1 0 5 32 38 (31)
Respiratory insufficiency 0 0 11 4 15 (12)
Intracranial bleeding 4 0 0 6 10 (8)
31-36 wk (n=92)d
Asphyxia 7 1 2 10 20 (22)
Congenital anomalies 1 6 7 20 34 (37)
Sepsis/necrotizing enterocolitis 1 3 1 16 21 (23)
Respiratory insufficiency 0 0 11 1 12 (13)
Intracranial bleeding 0 2 0 3 5 (5)
37 wk (n=144)e
Asphyxia 33 2 1 32 68 (47)
Congenital anomalies 4 30 5 14 53 (37)
Sepsis/necrotizing enterocolitis 0 0 0 13 13 (9)
Respiratory insufficiency 1 0 5 1 7 (5)
Intracranial bleeding 3 0 0 0 3 (2)
Abbreviation: MOF, multi-organ failure (if dysfunction of 2 or more organs led to death).
aMortality rate: (number of deaths/number of newborns admitted to the neonatal intensive care unit)100.15
bMortality rate of 15%.
cGestational age younger than 27 weeks.
dMortality rate of 5%.
eMortality rate of 10%.
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In 135 of 147 patients (92%), considerations regarding
the patient’s expected future quality of life were used and
mostly concerned predicted suffering or inability to be
engaged in any kind of communicationwith other people,
verbally or nonverbally. In 71 patients, considerations
regarding the infant’s present state with respect to qual-
ity of life were used, while in 64 patients, both types of
considerations were deemed important. Physicians re-
ported that parents had been involved in all decisions in
group II involving withdrawal of treatment.
COMMENT
This retrospective descriptive study investigated end-of-
life decisions in newborns in Dutch NICUs during the
course of 1 year. The study has yielded 3 important find-
ings. First, this study showed that end-of-life decisions
were made in 95% of all deaths. This indicates that phy-
sicians play a prominent role in the timing and modes
of death and dying in Dutch NICUs. Second, we report
that of all the newborns who died, 58% had been classi-
fied as having no chance of survival, while 42%were sta-
bilized newbornswith poor prognoses. In the latter group,
most end-of-life decisions were based on the infant’s fu-
ture quality of life and mainly concerned future suffer-
ing (76%). Third, we found only 1 case of deliberate end-
ing of a newborn’s life. This suggests that deliberate ending
of life in severely ill newborns may occur less frequently
in the Netherlands than was previously assumed.
More than 95% of deaths in the NICUs in our study
occurred after withdrawing or withholding of poten-
tially life-saving treatment. This proportion is substan-
tially higher than that described in the literature on neo-
natal end-of-life care dating from the 1970s and 1980s.16,17
It is also slightly higher than the rates reported more re-
cently in studies from other units in the United States,
Europe, andAustralia (58%-93%).1-4,6,10,18-22 A possible ex-
planation for the high rate is the use of different, more
restrictive definitions of end-of-life decisions in other stud-
ies.2,3 In our study, the decision to withdraw a ventilator
in newborns who were dying was taken as an end-of-life
decision, whereas in other studies, these cases were clas-
sified as deaths despite maximal support3 or had un-
clear classification.18,19 Another explanation could be that
legal support for treatment withdrawal in the Nether-
lands might make physicians more willing to document
end-of-life decisions. The high rate may reflect the re-
ferral base of the NICUs. In the Netherlands, high-risk
neonatal care is centralized in the 10 NICUs, and refer-
ral of severely ill newborns takes place at least partly to
ensure careful end-of-life decision making. Moreover, it
is likely to reflect the prevailing approach of Dutch neo-
natologists. Physician end-of-life decisionmakinghas been
a topic of debate for several decades in the Nether-
lands.12,23,24 From1990 to 1997, reports by theRoyalDutch
Medical Association and by the Dutch Pediatric Asso-
ciation on the medical and ethical acceptability of end-
of-life decisions were published and reflect the views of
the medical profession on the subject.13,25 Two situa-
tions forwithholding orwithdrawing life-sustaining treat-
ment are recognized: first, when there is no chance of
treatment succeeding and death is imminent (compa-
rable with group I in our study), and second, when de-
spite survival being possible, the outcome for the infant
is predicted to be extremely poor (group II). With re-
spect to the newborns in the first group, it is regarded as
less than ideal for a patient to die while hooked up to a
ventilator; therefore, artificial ventilation is withdrawn
preferably before the actual dying process (with brady-
cardia, etc) begins.12 This is done to give the parents the
opportunity to say their goodbyes and to let the infant
die in what physicians perceive as a dignified way: in the
arms of the parents and disconnected from a ventilator.
With regard to the newborns in the second group, the
position is held that not only is the survival of the
infant important but also the future child’s quality of
life, if he or she were to survive. Intensive care treat-
ment is used to overcome a life-threatening period in
life and it should only be initiated and continued
when there is a reasonable prognosis for the infant
after this period.13 Both reports share the view that
both the life-ending and life-prolonging decisions
should be legitimized. According to these reports, pro-







Asphyxia 41 (20) 57 (38)c
Congenital anomalies 69 (33) 25 (17)c
Sepsis/necrotizing enterocolitis 50 (24) 26 (17)
Extreme prematurityd 14 (7) 24 (16)c
Respiratory insufficiency 25 (12) 9 (6)
Intracranial bleeding 9 (4) 9 (6)
aUnstable newborns whose death was imminent.
bStabilized newborns with a very poor prognosis who were dependent on
intensive care for survival.
cP .05.
dGestational age younger than 27 weeks.
Table 4. Considerations Used for End-of-Life Decisions
in 147 Newborns With Very Poor Prognosesa
Characteristic No. of Cases
Considerations regarding the newborn’s present
state with respect to quality of life
Treatment does not contribute to medical
condition
48
Treatment is disproportionate 33
Considerations regarding the future quality of lifeb
Predicted inability to be engaged in any kind of
communication with other people, verbally or
nonverbally
18
Predicted lack of self-sufficiency 2
Expected hospital dependency 2
Predicted sufferingc 112
aGroup II. From interviews with the responsible physician; 3 interviews
were missing.
bAccording to previously published classification.13
c In this category, suffering encompasses pain, dyspnea, and other kinds
of physical suffering but also the burden suffered by the patient resulting
from anomalies in the other categories, including the suffering that is
intrinsic to having a disability.
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longation of intensive care treatment in situations in
which the prognosis is very grim might not always be
in the infant’s best interest. The quality-of-life consid-
erations, as operationalized in the reports, should be
bound strictly to medical criteria.14
In the Netherlands, end-of-life decisions are initiated
by physicians and parents are virtually always in-
volved.26,27 Consensus between parents and the team is
always reached. Although this division of roles is con-
sidered appropriate in the Netherlands, it can be chal-
lenged. The physicians’ prominent role may mean that
they also control the nature and amount of information
that they offer the parents and that they sometimesmake
decisions in situations in which their perspectives may
be limited or colored. Several studies have suggested that
intensivists routinely overestimate bad outcomes and con-
flate acute critical illness with long-term prognosis.28-33
In addition, the question remains how the best interest
of the infant should be defined and whether or not the
physician is the best person to make that judgment.
Our second finding that in 42% of deaths quality-of-
life considerationswere used to justifywithdrawal orwith-
holding of therapy is difficult to compare with other re-
ports on newborn end-of-life care because most studies
describe the physician’s attitude regarding end-of-life de-
cisions and not the practice.31,32,34-37 Even when with-
drawal of care is described, the distinction is rarely made
between the newborns who would have died despite in-
tensive interventions (group I) and those who were ex-
tubated for quality-of-life reasons (group II).7,18,38-40 Only
2 studies report on withdrawal of therapy for quality-of-
life reasons in roughly equivalent groups in 5% to 16%
of deaths.2,3
Two types of quality-of-life considerations can be dis-
tinguished in our results: those concerning the infant’s
present state (used in 48% of the decisions) and those
concerning the infant’s expected future state (used in 92%
of cases).Our findings confirm thatDutch physicians con-
sider future quality of life to be critically important. They
are prepared towithhold orwithdraw life-sustaining treat-
ment exclusively based on the predicted quality of life.
In virtually all end-of-life decisions, consultation took
place with other physicians and parents were always in-
volved. The high rate of involvement of other physi-
cians and parents may reflect the physicians’ awareness
that decisions concerning quality of life can never be based
on a single opinion.
A concern about the high rate of quality-of-life consid-
erations is that the outcome of the decision-making pro-
cess could become highly dependent on the physician’s
opinion about what is in the infant’s best interest, specifi-
cally with respect to the child’s future disability.Whether
this is compatiblewith the infant’s legal right to equal treat-
ment in equal cases and protection against discrimina-
tion under international human rights law is currently un-
der discussion41; we are also investigating this topic.
Our third finding concerned a single patient in group
III with type II osteogenesis imperfecta, whose death was
retrospectively categorized as deliberate ending of life.
Twoprevious surveys on end-of-life decisions in theNeth-
erlands reported that deliberate ending of life in new-
borns not dependent on life-sustaining treatment pre-
ceded 1% of deaths.7,20 This proportion represents 15 to
20 cases annually. One report from Flanders reported a
mortality rate of 7%, mainly in newborns before the sev-
enth day of life.4 Our study suggests that the frequency
of deliberate ending of life may have dropped consider-
ably. A possible explanation could be the improved and
more accessible prenatal screening resulting inmore ter-
minations of pregnancies with congenital malforma-
tions.42 This relates to the fact that since 2006, all preg-
nant women in the Netherlands have been able to
participate in an ultrasonography program for the de-
tection of congenital anomalies at 20 weeks’ gestation.
However, the incidence reported in our study needs to
be considered with caution, as we could not disregard
that a newborn in group III may have been referred from
the NICU to a local hospital (without a NICU) or dis-
charged home, where deliberate ending of life took place.
In group III we also did not include cases in which death
might have been caused by the use of palliative caremedi-
cation with potentially life-shortening effects around the
time ofwithdrawal of life-sustaining therapy. Another rel-
evant consideration is that estimations from the surveys
could have been based on a different classification of end-
of-life decisions and regarded newborns as younger than
12months.We restricted our study to newborns younger
than 2 months.
In the Netherlands, the decision to deliberately end a
newborn’s life is regarded legally and morally very dif-
ferently from the decision to withhold or withdraw life-
sustaining therapy. The first is in principle a criminal of-
fense (murder or homicide), whereas the latter is in
principle a medical decision that can be without conse-
quences in the field of criminal law. Based on 2 court cases
held in the mid-1990s, known as the Prins and Kadijk
cases,43,44 it is now accepted under certain circum-
stances that the physician who deliberately ends a new-
born’s life can claim impunity, ie, the defense of neces-
sity. In such circumstances, the patient’s suffering should
be extreme, thus compelling the physician to choose be-
tween the duty to save lives on the one hand and to do
everything possible to prevent unbearable suffering on
the other. If the physician then exercises due care and
reports the case to the juridical authorities, deliberate end-
ing of lifemay be justified. The requirements of duemedi-
cal care were formulated for the first time in the Prins
and Kadijk cases. These requirements also constitute the
fundaments of the Groningen Protocol for the deliber-
ate ending of life in severely ill newborns.8
During the period of our study, physicians had the le-
gal obligation to report all cases of the deliberate ending
of the life of newborns to the juridical authorities.8 We
were unable to determine why the group III case was not
reported. Previous studies have suggested that some other
acts of deliberate ending of life in newborns in the past
may also have remained unreported.10,45 A nationwide sur-
vey examined the physician’s opinion regarding the re-
porting procedure in 1994 and reported the lack of clar-
ity of the review procedure as a key reason for physicians’
nonreporting.7 After repeated requests for more trans-
parency and clarity about the review procedure of delib-
erate termination of life of newborns, in 2007 the Dutch
government established a multidisciplinary expert com-
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mittee to review these cases. The committee advises the
public prosecution if the physician has acted in accor-
dancewith specific requirements of careful practice.46 The
effects of these recent developments on the physician’s
preparedness to report their cases of deliberate ending
of life in the future are yet to be established.
We recognize several limitations to this study. The first
is its retrospective nature, though the fact that the medi-
cal files were available for scrutiny during the inter-
views may have limited potential inaccuracy in the phy-
sicians’ recall. Another limitation is that findings are based
on the physicians’ perception and not on those of other
care providers or the parents. Finally, as legal immunity
could not be guaranteed, we cannot exclude the possi-
bility that, despite our measures to ensure that the study
was held anonymously, the physicians’ responses in re-
lation to the deliberate ending of life might not always
reflect actual practice. A strength of our study is that all
NICUs in the Netherlands participated.
In conclusion, we have found that virtually all deaths
in Dutch NICUs are preceded by the decision to with-
draw life-sustaining treatment and many decisions are
based on the predicted future quality of life. Deliberate
ending of life in severely ill newbornsmay occur less fre-
quently than was previously assumed.
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